Lipoxygenase inhibitors for cancer prevention: Promises and risks

Current Pharmaceutical Design

Volumn 16, Issue 6, 2010, Pages 725-733

  Menna, Cecilia ^a   Olivieri, Fabiola ^b,c   Catalano, Alfonso ^b   Procopio, Antonio ^b,c  

^a DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^c INRCA   (Italy)

Author keywords

Cancer prevention; Cellular senescence; Lipoxygenase inhibitors

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; LINOLEIC ACID; LIPOXYGENASE; LIPOXYGENASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; POLYUNSATURATED FATTY ACID; PROSTAGLANDIN SYNTHASE; ANTINEOPLASTIC AGENT;

AEROBIC METABOLISM; ANTINEOPLASTIC ACTIVITY; CARCINOGENESIS; CHEMOPROPHYLAXIS; DIETARY INTAKE; ENZYME INHIBITION; FAT INTAKE; GASTROINTESTINAL TRACT; GENE EXPRESSION; GENETIC POLYMORPHISM; HUMAN; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SENESCENCE; ANIMAL; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; NEOPLASMS; OXIDATIVE STRESS; PHYSIOLOGY; RISK FACTOR; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; LIPOXYGENASE; LIPOXYGENASE INHIBITORS; NEOPLASMS; OXIDATIVE STRESS; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 77950259354     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210790883822     Document Type: Review

References (142)

1. Lucenteforte E, Talamini R, Montella M, Dal Maso L, Tavani A, Deandrea S, et al. Macronutrients, fatty acids and cholesterol intake and endometrial cancer. Ann Oncol 2008; 19: 168-172
2. Bahmanyar S, Ye W. Dietary patterns and risk of squamous-cell carcinoma and adenocarcinoma of the esophagus and adenocarcinoma of the gastric cardia: a population-based casecontrol study in Sweden. Nutr Cancer 2006; 54: 171-178
3. Biasi F, Mascia C, Poli G. The contribution of animal fat oxidation products to colon carcinogenesis, through modulation of TGF-beta1 signaling. Carcinogenesis 2008; 29: 890-894
4. Leitzmann MF, Stampfer MJ, Michaud DS, Augustsson K, Colditz GC, Willett WC, et al. Dietary intake of n-3 and n-6 fatty acids and the risk of prostate cancer. Am J Clin Nutr 2004; 80: 204-216
5. Schmitz G, Ecker J. The opposing effects of n-3 and n-6 fatty acids. Prog Lipid Res 2008; 47: 147-155
6. Schneider C, Boeglin WE, Yin H, Stec DF, Voehler M. Convergent oxygenation of arachidonic acid by 5-lipoxygenase and cyclooxygenase-2. J Am Chem Soc 2006; 128: 720-721
7. Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999; 18: 7908-7916
8. Wang D, DuBois RN. Pro-inflammatory prostaglandins and progression of colorectal cancer. Cancer Lett 2008; 267: 197-203.
9. Danese S. Inflammatory bowel disease and inflammation-associated colon cancer: partners in crime. Curr Drug Targets 2008; 9: 360.
10. 2. Oncology 2005; 69: 28-32.
11. 2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 2002; 8: 289-293
12. Wang D, Wang H, Shi Q, Katkuri S, Walji W, Desvergne B, et al. Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor delta. Cancer Cell 2004; 6: 285-295
13. 2 stimulates the growth of colon cancer cells via induction of amphiregulin. Cancer Res 2003; 63: 5218-5223
14. 2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem 2003; 278: 35451-35457
15. Meira LB, Bugni JM, Green SL, Lee CW, Pang B, Borenshtein D, et al. DNA damage induced by chronic inflammation contributes to colon carcinogenesis in mice. J Clin Invest 2008; 118: 2516-2525
16. MacFarlane AJ, Stover PJ. Convergence of genetic, nutritional and inflammatory factors in gastrointestinal cancers. Nutr Rev 2007; 65: S157-66.
17. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005; 7: 211-217
18. Vane JR, Botting RM. Mechanism of action of nonsteroidal antiinflammatory drugs. Am J Med 1998; 104: 2S-8S.
19. Cruz-Correa M, Hylind LM, Romans KE, Booker SV, Giardiello FM. Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study. Gastroenterology 2002; 122: 641-645
20. Das D, Arber N, Jankowski JA. Chemoprevention of colorectal cancer. Digestion 2007; 76:51-67.
21. Brown JR, DuBois RN. COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol 2005; 23: 2840-2855
22. Gupta RA, Dubois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001; 1: 11-21.
23. Lamont EB, Dias LE, Lauderdale DS. NSAIDs and colorectal cancer risk: do administrative data support a chemopreventive effect? J Gen Intern Med 2007; 22: 1166-1171
24. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107: 1183-1188
25. Das D, Arber N, Jankowski JA. Chemoprevention of colorectal cancer. Digestion 2007; 76: 51-67.
26. Courtney ED, Melville DM, Leicester RJ. Review article: chemoprevention of colorectal cancer. Aliment Pharmacol Ther 2004; 19: 1-24.
27. Wang D, Dubois RN. Prostaglandins and cancer. Gut 2006; 55: 115-122
28. 2 promotes angiogenesis in colorectal cancer. J Exp Med 2006; 203: 941-951
29. Sonoshita M, Takaku K, Sasaki N, Sugimoto Y, Ushikubi F, Narumiya S, et al. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc (Delta716) knockout mice. Nat Med 2001; 7: 1048-1051
30. 2 administration. Carcinogenesis 2003; 24: 985-990
31. 2. Oncology 2005; 69: 28-32.
32. Subbaramaiah K, Dannenberg AJ. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci 2003; 24: 96-102.
33. Sheng H, Shao J, Kirkland SC, Isakson P, Coffey RJ, Morrow J, et al. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 1997; 99: 2254-2259
34. Taha AS, Hudson N, Hawkey CJ, Swannell AJ, Trye PN, Cottrell J, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med 1996; 334: 1435-1439
35. Sporn MB, Liby KT. Cancer chemoprevention: scientific promise, clinical uncertainty. Nat Clin Pract Oncol 2005; 2: 518-525
36. Mann JR, Backlund MG, DuBois RN. Mechanisms of disease: inflammatory mediators and cancer prevention. Nat Clin Pract Oncol 2005; 2: 202-210
37. Jakobsson PJ, Thoren S, Morgenstern R, Samuelsson B. Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc Natl Acad Sci USA 1999; 96: 7220-7225
38. 2 synthase-1 in breast cancer: a potential target for therapy. J Pathol 2006; 208: 356-363
39. Tetsu O, McCormick F. ß-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999; 398: 422-426
40. 2 regulates the nuclear receptor NR4A2 in colorectal cancer. J Biol Chem 2006; 281: 2676-2682
41. Brash, A. R. Lipoxygenases: occurrence, functions, catalysis, and acquisition of substrate. J Biol Chem 1999; 274: 23679-23682
42. Lewis RA, Austen KF, Soberman RJ. Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N Engl J Med 1990; 323: 645-655
43. Reid GK, Kargman S, Vickers PJ, Mancini JA, Léveillé C, Either D, et al. Correlation between expression of 5-lipoxygenaseactivating protein, 5-lipoxygenase, and cellular leukotriene synthesis. J Biol Chem 1990; 265: 19818-19823
44. Jiang WG, Douglas-Jones AG, Mansel RE. Aberrant expression of 5-lipoxygenase-activating protein (5-LOXAP) has prognostic and survival significance in patients with breast cancer. Prostaglandins Leukot Essent Fatty Acids 2006; 74: 125-134
45. Klemm J, Samuelsson B, Rådmark O. 5-lipoxygenase is phosphorylated by p38 kinase-dependent MAPKAP kinases. Proc Natl Acad Sci USA 2000; 97: 5261-5266
46. Flamand N, Lefebvre J, Surette ME, Picard S, Borgeat P. Arachidonic acid regulates the translocation of 5-lipoxygenase to the nuclear membranes in human neutrophils. J Biol Chem 2006; 281: 129-136
47. Brash AR, Boeglin WE, Chang MS. Discovery of a second 15S-lipoxygenase in humans. Proc Natl Acad Sci USA 1997; 94: 6148-6152
48. Catalano A, Procopio A. New aspects on the role of lipoxygenases in cancer progression. Histol Histopathol 2005; 20: 969-975
49. Pidgeon GP, Lysaght J, Krishnamoorthy S, Reynolds JV, O'Byrne K, Nie D, et al. Lipoxygenase metabolism: roles in tumor progression and survival. Cancer Metastasis Rev 2007; 26: 503-524
50. Fürstenberger G, Krieg P, Müller-Decker K, Habenicht AJ. What are cyclooxygenases and lip oxygenases doing in the driver's seat of carcinogenesis? Int J Cancer 2006; 119: 2247-2254
51. Shureiqi I, Wu Y, Chen D, Yang XL, Guan B, Morris JS, et al. The Critical role of 15-lipoxygenase-1 in colorectal epithelial cell terminal differentiation and tumorigenesis. Cancer Res 2005; 65: 11486-11492
52. Myrdal PB, Karlage K, Kuehl PJ, Angersbach BS, Merrill BA, Wightman PD. Effects of novel 5-lipoxygenase inhibitors on the incidence of pulmonary adenomas in the A/J murine model when administered via nose-only inhalation. Carcinogenesis 2007; 28: 957-961
53. Nelson MA. Inhibition of lipoxygenase activity: implications for the treatment and chemoprevention of prostate cancer. Cancer Biol Ther 2007; 6: 237.
54. Soumaoro LT, Iida S, Uetake H, Ishiguro M, Takagi Y, Higuchi T, et al. Expression of 5-lipoxygenase in human colorectal cancer. World J Gastroenterol 2006; 12: 6355-6360
55. Wu X, Biswal SS, Kehrer JP. Roles of 5-lipoxygenase activating protein in cell proliferation and apoptosis. Cell Biol Toxicol 2003; 19: 135-143
56. Romano M, Catalano A, Nutini M, D'Urbano E, Crescenzi C, Claria J, et al. 5-lipoxygenase regulates malignant mesothelial cell survival: involvement of vascular endothelial growth factor. FASEB J 2001; 15: 2326-2336
57. Nie D, Honn KV. Cyclooxygenase, lipoxygenase and tumor angiogenesis. Cell Mol Life Sci 2002; 59: 799-807.
58. Catalano A, Caprari P, Soddu S, Procopio A, Romano M. 5-lipoxygenase antagonizes genotoxic stress-induced apoptosis by altering p53 nuclear trafficking. FASEB J 2004; 18: 1740-1742
59. Catalano A, Rodilossi S, Caprari P, Coppola V, Procopio A. 5- Lipoxygenase regulates senescence-like growth arrest by promoting ROS-dependent p53 activation. EMBO J 2005; 24: 170-179
60. Funk CD, Hoshiko S, Matsumoto T, Rdmark O, Samuelsson B. Characterization of the human 5-lipoxygenase gene. Proc Natl Acad Sci USA. 1989; 86: 2587-2591
61. Uhl J, Klan N, Rose M, Entian KD, Werz O, Steinhilber D. The 5-lipoxygenase promoter is regulated by DNA methylation. J Biol Chem 2002; 277: 4374-4379
62. Jatana M, Giri S, Ansari MA, Elango C, Singh AK, Singh I, et al. Inhibition of NF-κB activation by 5-lipoxygenase inhibitors protects brain against injury in a rat model of focal cerebral ischemia. J Neuroinflammation 2006; 3: 12.
63. Chung SW, Toriba A, Chung HY, Yu BP, Kameda T, Tang N, et al. Activation of 5-lipoxygenase and NF-kappa B in the action of acenaphthenequinone by modulation of oxidative stress. Toxicol Sci 2008; 101: 152-158
64. Gupta S, Srivastava M, Ahmad N, Sakamoto K, Bostwick DG, Mukhtar H. Lipoxygenase-5 is overexpressed in prostate adenocarcinoma. Cancer 2001; 91: 737-743
65. Hennig R, Ding XZ, Tong WG, Schneider MB, Standop J, Friess H, et al. 5-Lipoxygenase and leukotriene B(4) receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue. Am J Pathol 2002; 161: 421-428
66. Ohd JF, Nielsen CK, Campbell J, Landberg G, Lofberg H, Sjolander A. Expression of the leukotriene D4 receptor CysLT1, COX-2, and other cell survival factors in colorectal adenocarcinomas. Gastroenterology 2003; 124: 57-70.
67. Yoshimura R, Matsuyama M, Tsuchida K, Kawahito Y, Sano H, Nakatani T. Expression of lipoxygenase in human bladder carcinoma and growth inhibition by its inhibitors. J Urol 2003; 170: 1994-1999
68. Yoshimura R, Matsuyama M, Mitsuhashi M, Takemoto Y, Tsuchida K, Kawahito Y, et al. Relationship between lipoxygenase and human testicular cancer. Int J Mol Med 2004; 13: 389-393
69. Chen X, Wang S, Wu N, Sood S, Wang P, Jin Z, et al. Overexpression of 5-lipoxygenase in rat and human esophageal adenocarcinoma, and inhibitory effects of zileuton and celecoxib on carcinogenesis. Clin Cancer Res 2004; 10: 6703-6709
70. Faronato M, Muzzonigro G, Milanese G, Menna C, Bonfigli AR, Catalano A, et al. Increased expression of 5-lipoxygenase is common in clear renal cell carcinoma. Histol Histopathol 2007; 22: 1109-1118
71. Steele VE, Holmes CA, Hawk ET, Kopelovich L, Lubet RA, Crowell JA, et al. Lipoxygenase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev 1999; 8: 467-483
72. Gunning WT, Kramer PM, Steele VE, Pereira MA. Chemoprevention by lipoxygenase and leukotriene pathway inhibitors of vinyl carbamate-induced lung tumors in mice. Cancer Res 2002; 62: 4199-4201
73. Jiang H, Yamamoto S, Kato R. Inhibition of two-stage skin carcinogenesis as well as complete skin carcinogenesis by oral administration of TMK688, a potent lipoxygenase inhibitor. Carcinogenesis 1994; 15: 807-812
74. Wenger FA, Kilian M, Achucarro P, Heinicken D, Schimke I, Guski H, et al. Effects of Celebrex and Zyflo on BOP-induced pancreatic cancer in Syrian hamsters. Pancreatology 2002; 2: 54-60.
75. Jiang WG, Douglas-Jones AG, Mansel RE. Aberrant expression of 5-lipoxygenase-activating protein (5-LOXAP) has prognostic and survival significance in patients with breast cancer. Prostaglandins Leukot Essent Fatty Acids 2006; 74: 125-134
76. Campisi J. Cellular senescence as a tumor-suppressor mechanism. Trends Cell Biol 2001; 11: 27-31.
77. Parrinello S, Samper E, Krtolica A, Goldstein J, Melov S, Campisi J. Oxygen sensitivity severely limits the replicative lifespan of murine fibroblasts. Nat Cell Biol 2003; 5: 741-747
78. Haendeler J, Hoffmann J, Diehl JF, Vasa M, Spyridopoulos I, Zeiher AM, et al. Antioxidants inhibit nuclear export of telomerase reverse transcriptase and delay replicative senescence of endothelial cells. Circ Res 2004; 94: 768-775
79. Dincbas-Renqvist V, Pépin G, Rakonjac M, Plante I, Ouellet DL, Hermansson A, et al. Human Dicer C-terminus functions as a 5-lipoxygenase binding domain. Biochim Biophys Acta 2009; 1789: 99-108.
80. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297
81. Barbarotto E, Schmittgen TD, Calin GA. MicroRNAs and cancer: profile, profile, profile. Int J Cancer 2008; 122 : 969-977
82. Yoshimura R, Inoue K, Kawahito Y, Mitsuhashi M, Tsuchida K, Matsuyama M, et al. Expression of 12-lipoxygenase in human renal cell carcinoma and growth prevention by its inhibitor. Int J Mol Med 2004; 13: 41-46
83. Nie D, Krishnamoorthy S, Jin R, Tang K, Chen Y, Qiao Y, et al. Mechanisms regulating tumor angiogenesis by 12-lipoxygenase in prostate cancer cells. J Biol Chem 2006; 281: 18601-18609
84. Rásó E, Döme B, Somlai B, Zacharek A, Hagmann W, Honn KV, et al . Molecular identification, localization and function of platelettype 12-lipoxygenase in human melanoma progression, under experimental and clinical conditions. Melanoma Res 2004; 14: 245-250
85. Winer I, Normolle DP, Shureiqi I, Sondak VK, Johnson T, Su L, et al. Expression of 12-lipoxygenase as a biomarker for melanoma carcinogenesis. Melanoma Res 2002; 12: 429-434
86. Piao YS, Du YC, Oshima H, Jin JC, Nomura M, Yoshimoto T, et al. Platelet-type 12-lipoxygenase accelerates tumor promotion of mouse epidermal cells through enhancement of cloning efficiency. Carcinogenesis 2008; 29: 440-447
87. Endsley MP, Aggarwal N, Isbell MA, Wheelock CE, Hammock BD, Falck JR, et al. Diverse roles of 2-arachidonoylglycerol in invasion of prostate carcinoma cells: Location, hydrolysis and 12- lipoxygenase metabolism. Int J Cancer 2007; 121: 984-991
88. Nie D, Krishnamoorthy S, Jin R, Tang K, Chen Y, Qiao Y, et al. Mechanisms regulating tumor angiogenesis by 12-lipoxygenase in prostate cancer cells. J Biol Chem 2006; 281: 18601-18609
89. Chen FL, Wang XZ, Li JY, Yu JP, Huang CY, Chen ZX.12-lipoxygenase induces apoptosis of human gastric cancer AGS cells via the ERK1/2 signal pathway. Dig Dis Sci 2008; 53: 181-187
90. Pidgeon GP, Lysaght J, Krishnamoorthy S, Reynolds JV, O'Byrne K, Nie D, et al. Lipoxygenase metabolism: roles in tumor progression and survival. Cancer Metastasis Rev 2007; 26: 503-524
91. Wu Y, Fang B, Yang XQ, Wang L, Chen D, Krasnykh V, et al. Therapeutic molecular targeting of 15-lipoxygenase-1 in colon cancer. Mol Ther 2008; 16: 886-892
92. Shureiqi I, Jiang W, Zuo X, Wu Y, Stimmel JB, Leesnitzer LM, et al. The 15-lipoxygenase-1 product 13-S-hydroxyoctadecadienoic acid down-regulates PPAR-delta to induce apoptosis in colorectal cancer cells. Proc Natl Acad Sci USA 2003; 100: 9968-9973
93. Shureiqi I, Jiang W, Fischer SM, Xu X, Chen D, Lee JJ, et al. GATA-6 transcriptional regulation of 15-lipoxygenase-1 during NSAID-induced apoptosis in colorectal cancer cells. Cancer Res 2002; 62: 1178-1183
94. Shureiqi I, Zuo X, Broaddus R, Wu Y, Guan B, Morris JS, et al. The transcription factor GATA-6 is overexpressed in vivo and contributes to silencing 15-LOX-1 in vitro in human colon cancer. FASEB J 2007; 21: 743-753
95. Kamitani H, Kameda H, Kelavkar UP, Eling TE. A GATA binding site is involved in the regulation of 15-lipoxygenase-1 expression in human colorectal carcinoma cell line, caco-2. FEBS Lett. 2000; 467: 341-347
96. Shureiqi I, Jiang W, Zuo X, Wu Y, Stimmel JB, Leesnitzer LM, et al. The 15-lipoxygenase-1 product 13-S-hydroxyoctadecadienoic acid down-regulates PPAR-delta to induce apoptosis in colorectal cancer cells. Proc Natl Acad Sci USA 2003; 100: 9968-9973
97. Kelavkar UP, Harya NS, Hutzley J, Bacich DJ, Monzon FA, Chandran U, et al. DNA methylation paradigm shift: 15-lipoxygenase-1 upregulation in prostatic intraepithelial neoplasia and prostate cancer by atypical promoter hypermethylation. Prostaglandins Other Lipid Mediat 2007; 82: 185-197
98. Tang DG, Bhatia B, Tang S, Schneider-Broussard R. 15-lipoxygenase 2 (15-LOX2) is a functional tumor suppressor that regulates human prostate epithelial cell differentiation, senescence, and growth (size). Prostaglandins Other Lipid Mediat 2007; 82: 135-146
99. Shureiqi I, Lippman SM. Lipoxygenase modulation to reverse carcinogenesis. Cancer Res 2001; 61: 6307-6312
100. Spanbroek R, Hildner M, Kohler A, Muller A, Zintl F, Kuhn H, et al. IL-4 determines eicosanoid formation in dendritic cells by down-regulation of 5-lipoxygenase and up-regulation of 15-lipoxygenase 1 expression. Proc Natl Acad Sci USA 2001; 98: 5152-5157
101. Kuhn H, Heydeck D, Brinckman R, Trebus F. Regulation of cellular 15-lipoxygenase activity on pretranslational, translational, and posttranslational levels. Lipids 1999; 34: S273-79.
102. Kamitani H, Kameda H, Kelavkar UP, Eling TE. A GATA binding site is involved in the regulation of 15-lipoxygenase-1 expression in human colorectal carcinoma cell line, caco-2. FEBS Lett 2000; 467: 341-347
103. Ohd JF, Nielsen CK, Campbell J, Landberg G, Löfberg H, Sjölander A. Expression of the leukotriene D4 receptor CysLT1, COX-2, and other cell survival factors in colorectal adenocarcinomas. Gastroenterology 2003; 124: 57-70.
104. Lin HJ, Lakkides KM, Keku TO, Reddy ST, Louie AD, Kau IH, et al. Prostaglandin H synthase 2 variant (Val511Ala) in African Americans may reduce the risk for colorectal neoplasia. Cancer Epidemiol Biomarkers Prev 2002; 11: 1305-1315
105. Sansbury LB, Millikan RC, Schroeder JC, North KE, Moorman PG, Keku TO, et al. COX-2 polymorphism, use of nonsteroidal antiinflammatory drugs, and risk of colon cancer in African Americans (United States). Cancer Causes Control 2006; 17: 257-266
106. Goodman JE, Bowman ED, Chanock SJ, Alberg AJ, Harris CC. Arachidonate lipoxygenase (ALOX) and cyclooxygenase (COX) polymorphisms and colon cancer risk. Carcinogenesis 2004; 25: 2467-2472
107. Cox DG, Pontes C, Guino E, Navarro M, Osorio A, Canzian F, et al. Polymorphisms in prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) and risk of colorectal cancer. Br J Cancer 2004; 91: 339-343
108. Tan W, Wu J, Zhang X, Guo Y, Liu J, Sun T, et al. Associations of functional polymorphisms in cyclooxygenase-2 and platelet 12-lipoxygenase with risk of occurrence and advanced disease status of colorectal cancer. Carcinogenesis 2007; 28: 1197-1201
109. Koh WP, Yuan JM, van den Berg D, Lee HP, Yu MC. Interaction between cyclooxygenase-2 gene polymorphism and dietary n-6 polyunsaturated fatty acids on colon cancer risk: the Singapore Chinese Health Study. Br J Cancer 2004; 90: 1760-1764
110. Ueda N, Maehara Y, Tajima O, Tabata S, Wakabayashi K, Kono S. Genetic polymorphisms of cyclooxygenase-2 and colorectal adenoma risk: the Self Defense Forces Health Study. Cancer Sci 2008; 99: 576-581
111. Ulrich CM, Whitton J, Yu JH, Sibert J, Sparks R, Potter JD, et al. PTGS2 (COX-2) -765G >C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal anti-inflammatory drugs. Cancer Epidemiol Biomarkers Prev 2005; 14: 616-619
112. Papafili A, Hill MR, Brull DJ, McAnulty RJ, Marshall RP, Humphries SE, et al. Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Arterioscler Thromb Vasc Biol 2002; 22: 1631-1636
113. Brosens LA, Iacobuzio-Donahue CA, Keller JJ, Hustinx SR, Carvalho R, Morsink FH, et al. Increased cyclooxygenase-2 expression in duodenal compared with colonic tissues in familial adenomatous polyposis and relationship to the -765G →C COX-2 polymorphism. Clin Cancer Res 2005; 11: 4090-4096
114. Szczeklik W, Sanak M, Szczeklik A. Functional effects and gender association of COX-2 gene polymorphism G-765C in bronchial asthma. J Allergy Clin Immunol 2004; 114: 248-253
115. Zhang X, Miao X, Tan W, Ning B, Liu Z, Hong Y, et al. Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer. Gastroenterology 2005; 129: 565-576
116. Goodman JE, Bowman ED, Chanock SJ, Alberg AJ, Harris CC. Arachidonate lipoxygenase (ALOX) and cyclooxygenase (COX) polymorphisms and colon cancer risk. Carcinogenesis 2004; 25: 2467-2472
117. Koh WP, Yuan JM, van den Berg D, Lee HP, Yu MC. Interaction between cyclooxygenase-2 gene polymorphism and dietary n-6 polyunsaturated fatty acids on colon cancer risk: The Singapore Chinese Health Study. Br J Cancer 2004; 90: 1760-1764
118. Poole EM, Bigler J, Whitton J, Sibert JG, Potter JD, Ulrich CM. Prostacyclin synthase and arachidonate 5-lipoxygenase polymorphisms and risk of colorectal polyps. Cancer Epidemiol Biomarkers Prev 2006; 15: 502-508
119. Gong Z, Hebert JR, Bostick RM, Deng Z, Hurley TG, Dixon DA, et al. Common polymorphisms in 5-lipoxygenase and 12- lipoxygenase genes and the risk of incident, sporadic colorectal adenoma. Cancer 2007; 109: 849-857
120. Fridman C, Ojopi EP, Gregório SP, Ikenaga EH, Moreno DH, Demetrio FN, et al. Association of a new polymorphism in ALOX12 gene with bipolar disorder. Eur Arch Psychiatry Clin Neurosci 2003; 253: 40-43
121. Guo Y, Zhang X, Tan W, Miao X, Sun T, Zhao D, et al. Platelet 12-lipoxygenase Arg261Gln polymorphism: functional characterization and association with risk of esophageal squamous cell carcinoma in combination with COX-2 polymorphisms. Pharmacogenet Genomics 2007; 17: 197-205.
122. Tan XL, Nieters A, Hoffmeister M, Beckmann L, Brenner H, Chang-Claude J. Genetic polymorphisms in TP53, nonsteroidal anti-inflammatory drugs and the risk of colorectal cancer: evidence for gene-environment interaction? Pharmacogenet Genomics 2007; 17: 639-645
123. Ulrich CM, Bigler J, Potter JD. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer 2006; 6: 130-140
124. Goossens L, Pommery N, Hénichart JP. COX-2/5-LOX dual acting anti-inflammatory drugs in cancer chemotherapy. Curr Top Med Chem 2007; 7: 283-296
125. Dahlen SE. 5-Lipoxygenase inhibitors. New Drugs Asthma Allergy COPD 2001; 31: 115-120
126. Maharvi GM, Ali S, Riaz N, Afza N, Malik A, Ashraf M, et al. Mild and efficient synthesis of new tetraketones as lipoxygenase inhibitors and antioxidants. J Enzyme Inhib Med Chem 2008; 23: 62-69
127. Fiorucci S, Meli R, Bucci M, Cirino G. Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in antiinflammatory therapy? Biochem Pharmacol 2001; 62, 1433-1438
128. Parente L. Pros and cons of selective inhibition of cyclooxygenase-2 versus dual lipoxygenase/cyclooxygenase inhibition: is two better then one? J Rheumatol 2001, 28,:2375-2382
129. Reddy MV, Billa VK, Pallela VR, Mallireddigari MR, Boominathan R, Gabriel JL, et al. Design, synthesis, and biological evaluation of 1-(4-sulfamylphenyl) -3-trifluoromethyl-5-indolyl pyrazolines as cyclooxygenase-2 (COX-2) and lipoxygenase (LOX) inhibitors. Bioorg Med Chem 2008; 16: 3907-3916
130. Franceschi C, Olivieri F, Marchegiani F, Cardelli M, Cavallone L, Capri M, et al. Genes involved in immune response/inflammation, IGF1/insulin pathway and response to oxidative stress play a major role in the genetics of human longevity: the lesson of centenarians. Mech Ageing Dev 2005; 126: 351-361
131. Leval X, Julemont F, Delarge J, Pirotte B, Dogne JM. New trends in dual 5-LOX/COX inhibition. Curr Med Chem 2002; 9, 941-962
132. González-Périz A, Clària J. New approaches to the modulation of the cyclooxygenase-2 and 5-lipoxygenase pathways. Curr Top Med Chem 2007; 7: 297-309.
133. Hong J, Bose M, Ju J, Ryu JH, Chen X, Sang S, et al. Modulation of arachidonic acid metabolism by curcumin and related b-diketone derivatives: effects on cytosolic phospholipase A2, cyclooxygenases and 5-lipoxygenase. Carcinogenesis 2004; 25, 1671-1679
134. Reginster JY, Bias P, Buchner A. First clinical results of licofelone (ML3000), an inhibitor of COX-1, COX-2 and 5-LOX, for the treatment of osteoarhtritis. Ann Rheum Dis 2002; 61 :116-117
135. Tavolari S, Bonafè M, Marini M, Ferreri C, Bartolini G, Brighenti E, et al. Licofelone, a dual COX/5-LOX inhibitor, induces apoptosis in HCA-7 colon cancer cells through the mitochondrial pathway independently from its ability to affect the arachidonic acid cascade. Carcinogenesis 2008; 29: 371-380
136. Li N, Sood S, Wang S, Fang M, Wang P, Sun Z, et al. Overexpression of 5-lipoxygenase and cyclooxygenase 2 in hamster and human oral cancer and chemopreventive effects of zileuton and celecoxib. Clin Cancer Res 2005; 11: 2089-2096
137. Cianchi F, Cortesini C, Magnelli L, Fanti E, Papucci L, Schiavone N, et al. Inhibition of 5-lipoxygenase by MK886 augments the antitumor activity of celecoxib in human colon cancer cells. Mol Cancer Ther 2006; 5: 2716-2726
138. Schroeder CP, Yang P, Newman RA, Lotan R. Simultaneous inhibition of COX-2 and 5-LOX activities augments growth arrest and death of premalignant and malignant human lung cell lines. J Exp Ther Oncol 2007; 6: 183-192
139. Skelly MM, Hawkey CJ. COX-LOX inhibition: current evidence for an emerging new therapy. Int. J Clin Pract 2003, 57, 301-304
140. Schroeder CP, Yang P, Newman RA, Lotan R. Simultaneous inhibition of COX-2 and 5-LOX activities augments growth arrest and death of premalignant and malignant human lung cell lines. J Exp Ther Oncol 2007; 6: 183-192
141. Goossens L, Pommery N, Hénichart JP. COX-2/5-LOX dual acting anti-inflammatory drugs in cancer chemotherapy. Curr Top Med Chem 2007; 7: 283-296
142. Gaddi A, Cicero AF, Pedro EJ. Clinical perspectives of antiinflammatory therapy in the elderly: the lipoxigenase (LOX)/ cycloxigenase (COX) inhibition concept. Arch Gerontol Geriatr 2004; 38: 201-212